Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer.

Trial Profile

Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2013

At a glance

  • Drugs Docetaxel (Primary) ; Everolimus (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 27 Apr 2012 Actual patient number is 15 according to ClinicalTrials.gov.
    • 27 Apr 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov
    • 27 Apr 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top